Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02472977 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT02472977: Clinical Trial Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT02472977 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 61 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02472977, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.
Primary Outcome
The number participants who experienced on-study AEs, SAEs, and AEs requiring immune modulating medication is reported.
Interventions
- DRUG Nivolumab
- DRUG Ulocuplumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-07-13 |
| Est. Completion | 2017-01-27 |
| Phase | Phase 1 |
Why NCT02472977 stopped before completion
NCT02472977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02472977 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02472977 about?
NCT02472977 is a clinical study titled "Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors". The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.
What is the current status of trial NCT02472977?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2015-07-13. Estimated completion is 2017-01-27.
What interventions are being tested in trial NCT02472977?
The interventions under investigation include: Nivolumab (DRUG), Ulocuplumab (DRUG).
Who is sponsoring clinical trial NCT02472977?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02472977's enrollment target sits among peer trials
61 828th of 2000 higher than 1,170 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI